Joana Torres1, Francesca Petralia2, Takahiro Sato3, Pei Wang2, Shannon E Telesco3, Rok Seon Choung4, Richard Strauss3, Xiao-Jun Li5, Renee M Laird6, Ramiro L Gutierrez6, Chad K Porter6, Scott Plevy3, Fred Princen5, Joseph A Murray4, Mark S Riddle7, Jean-Frederic Colombel8. 1. Department of Medicine, Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York; Gastroenterology Division, Hospital Beatriz Ângelo, Loures, Lisbon, Portugal. 2. Department of Genetics and Genomic Sciences, Icahn School of Medicine, New York City, New York. 3. Janssen Research and Development, Spring House (Ambler), Pennsylvania. 4. Department of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota. 5. Prometheus Laboratories, San Diego, California. 6. Enteric Diseases Department, Naval Medical Research Center, Silver Spring, Maryland. 7. Enteric Diseases Department, Naval Medical Research Center, Silver Spring, Maryland; Department of Preventive Medicine and Biostatistics, Uniformed Services University, Bethesda, Maryland. Electronic address: markriddlemd@gmail.com. 8. Department of Medicine, Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: jean-frederic.colombel@mssm.edu.
Abstract
BACKGROUND & AIMS: Biomarkers are needed to identify patients at risk for development of inflammatory bowel diseases. We aimed to identify serum biomarkers of Crohn's disease and ulcerative colitis that can be detected and quantified before diagnosis. METHODS: We obtained serum samples from patients archived before a diagnosis of Crohn's disease (n = 200) or ulcerative colitis (n = 199), as well as from 200 healthy individuals (controls), collected from 1998 through 2013 as part of the US Defense Medical Surveillance System. We measured levels of antibodies against microbes (anti-Saccharomyces cerevisiae IgA or IgG, anti-Escherichiacoli outer membrane porin C, anti-CBir1, anti-flagellin 2, anti-flagellin X, and perinuclear anti-neutrophil cytoplasmic antibodies) and 1129 proteins in each sample. We then used functional principal component analysis to derive the time-varying trajectory for each marker, which then was used in a multivariate model to predict disease status. Predictive performances at different prediagnosis timepoints were evaluated using area under the receiver operating characteristic curves (AUROCs). Biological pathways that were up-regulated in serum from patients with Crohn's disease were identified based on changes in protein abundance at different time periods preceding diagnosis. RESULTS: We identified a panel of 51 protein biomarkers that were predictive of Crohn's disease within 5 years with an AUROC of 0.76 and a diagnosis within 1 year with an AUROC of 0.87. Based on the proteins included in the panel, imminent development of CD was associated with changes in the complement cascade, lysosomes, innate immune response, and glycosaminoglycan metabolism. Serum antibodies and proteins identified patients who received a diagnosis of ulcerative colitis within 5 years with an AUROC of only 0.56 and within 1 year with an AUROC of 0.72. CONCLUSIONS: We identified a panel of serum antibodies and proteins that were predictive of patients who will receive a diagnosis of Crohn's disease within 5 years with high accuracy. By contrast we did not identify biomarkers associated with future diagnosis of ulcerative colitis.
BACKGROUND & AIMS: Biomarkers are needed to identify patients at risk for development of inflammatory bowel diseases. We aimed to identify serum biomarkers of Crohn's disease and ulcerative colitis that can be detected and quantified before diagnosis. METHODS: We obtained serum samples from patients archived before a diagnosis of Crohn's disease (n = 200) or ulcerative colitis (n = 199), as well as from 200 healthy individuals (controls), collected from 1998 through 2013 as part of the US Defense Medical Surveillance System. We measured levels of antibodies against microbes (anti-Saccharomyces cerevisiae IgA or IgG, anti-Escherichiacoli outer membrane porin C, anti-CBir1, anti-flagellin 2, anti-flagellin X, and perinuclear anti-neutrophil cytoplasmic antibodies) and 1129 proteins in each sample. We then used functional principal component analysis to derive the time-varying trajectory for each marker, which then was used in a multivariate model to predict disease status. Predictive performances at different prediagnosis timepoints were evaluated using area under the receiver operating characteristic curves (AUROCs). Biological pathways that were up-regulated in serum from patients with Crohn's disease were identified based on changes in protein abundance at different time periods preceding diagnosis. RESULTS: We identified a panel of 51 protein biomarkers that were predictive of Crohn's disease within 5 years with an AUROC of 0.76 and a diagnosis within 1 year with an AUROC of 0.87. Based on the proteins included in the panel, imminent development of CD was associated with changes in the complement cascade, lysosomes, innate immune response, and glycosaminoglycan metabolism. Serum antibodies and proteins identified patients who received a diagnosis of ulcerative colitis within 5 years with an AUROC of only 0.56 and within 1 year with an AUROC of 0.72. CONCLUSIONS: We identified a panel of serum antibodies and proteins that were predictive of patients who will receive a diagnosis of Crohn's disease within 5 years with high accuracy. By contrast we did not identify biomarkers associated with future diagnosis of ulcerative colitis.
Authors: Antonella Fazio; Dora Bordoni; Jan W P Kuiper; Saskia Weber-Stiehl; Stephanie T Stengel; Philipp Arnold; David Ellinghaus; Go Ito; Florian Tran; Berith Messner; Anna Henning; Joana P Bernardes; Robert Häsler; Anne Luzius; Simon Imm; Finn Hinrichsen; Andre Franke; Samuel Huber; Susanna Nikolaus; Konrad Aden; Stefan Schreiber; Felix Sommer; Gioacchino Natoli; Neha Mishra; Philip Rosenstiel Journal: Nat Commun Date: 2022-10-21 Impact factor: 17.694
Authors: Calen A Steiner; Jeffrey A Berinstein; Jeremy Louissaint; Peter D R Higgins; Jason R Spence; Carol Shannon; Cathy Lu; Ryan W Stidham; Joel G Fletcher; David H Bruining; Brian G Feagan; Vipul Jairath; Mark E Baker; Dominik Bettenworth; Florian Rieder Journal: Clin Gastroenterol Hepatol Date: 2021-06-02 Impact factor: 11.382
Authors: Katie L Alexander; Qing Zhao; Meagan Reif; Alexander F Rosenberg; Peter J Mannon; Lennard Wayne Duck; Charles O Elson Journal: Gastroenterology Date: 2021-05-07 Impact factor: 33.883